Editorial: With Califf confirmed, FDA needs to return to priorities lost to the pandemic and improve its messaging

Zachary Brennan

Senior Editor

The pandemic is by no means over, and the FDA will surely continue to prioritize the necessary EUAs for additional therapies and targeted vaccines as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Editorial: With Califf confirmed, FDA needs to return to priorities lost to the pandemic and improve its messaging

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Ed­i­to­r­i­al: With Califf con­firmed, FDA needs to re­turn to pri­or­i­ties lost to the pan­dem­ic and im­prove its mes­sag­ing

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Editorial: With Califf confirmed, FDA needs to return to priorities lost to the pandemic and improve its messaging

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?